Revolution Medicines, Inc.RVMDEarnings & Financial Report
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
Revenue
$15.3M
Gross Profit
N/A
Operating Profit
$-61.7M
Net Profit
$-56.5M
Gross Margin
N/A
Operating Margin
-402.5%
Net Margin
-368.6%
YoY Growth
62.1%
EPS
$-0.61
Revolution Medicines, Inc. Q4 FY2022 Financial Summary
Revolution Medicines, Inc. reported revenue of $15.3M (up 62.1% YoY) for Q4 FY2022, with a net profit of $-56.5M (down 7.3% YoY) (-368.6% margin).
Key Financial Metrics
| Total Revenue | $15.3M |
|---|---|
| Net Profit | $-56.5M |
| Gross Margin | N/A |
| Operating Margin | -402.5% |
| Report Period | Q4 FY2022 |
Revolution Medicines, Inc. Annual Revenue by Year
Revolution Medicines, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2022 | $35.4M |
Revolution Medicines, Inc. Quarterly Revenue & Net Profit History
Revolution Medicines, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $0 | — | $-194.6M | N/A |
| Q3 FY2024 | $0 | — | $-156.3M | N/A |
| Q2 FY2024 | $0 | — | $-133.2M | N/A |
| Q1 FY2024 | $0 | — | $-116.0M | N/A |
| Q3 FY2023 | $0 | — | $-108.4M | N/A |
| Q2 FY2023 | $3.8M | -58.1% | $-98.3M | -2570.6% |
| Q1 FY2023 | $7.0M | -7.4% | $-68.1M | -970.9% |
| Q4 FY2022 | $15.3M | +62.1% | $-56.5M | -368.6% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.3M | $7.0M | $3.8M | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 62.1% | -7.4% | -58.1% | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $811.9M | $1.07B | $1.07B | $984.2M | $1.91B | $1.81B | $1.76B | $2.56B |
| Liabilities | $126.7M | $121.0M | $142.9M | $146.8M | $182.9M | $189.6M | $196.7M | $293.1M |
| Equity | $685.2M | $952.2M | $930.8M | $837.5M | $1.73B | $1.62B | $1.57B | $2.27B |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-61.8M | $-62.4M | $-67.1M | $-100.5M | $-160.6M | $-128.2M | $-130.4M | $-138.3M |